IP Verse

Blood-Based Biomarkers Of Tumor Sensitivity To Pd-1 Antagonists - EP3283882

The patent EP3283882 was granted to Merck Sharp & Dohme on Oct 16, 2024. The application was originally filed on Apr 12, 2016 under application number EP16780526A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3283882

MERCK SHARP & DOHME
Application Number
EP16780526A
Filing Date
Apr 12, 2016
Status
Patent Maintained As Amended
Sep 13, 2024
Grant Date
Oct 16, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SYMBIOSISSep 15, 2021SYMBIOSISADMISSIBLE

Patent Citations (83) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2014US70232
DESCRIPTIONWO2014US70236
DESCRIPTIONWO2014US70237
DESCRIPTIONUS2015071910
DESCRIPTIONUS4816567
DESCRIPTIONUS5143854
DESCRIPTIONUS5242974
DESCRIPTIONUS5288644
DESCRIPTIONUS5324633
DESCRIPTIONUS5384261
DESCRIPTIONUS5405783
DESCRIPTIONUS5412087
DESCRIPTIONUS5424186
DESCRIPTIONUS5429807
DESCRIPTIONUS5432049
DESCRIPTIONUS5436327
DESCRIPTIONUS5445934
DESCRIPTIONUS5470710
DESCRIPTIONUS5472672
DESCRIPTIONUS5492806
DESCRIPTIONUS5503980
DESCRIPTIONUS5510270
DESCRIPTIONUS5525464
DESCRIPTIONUS5527681
DESCRIPTIONUS5529756
DESCRIPTIONUS5545531
DESCRIPTIONUS5547839
DESCRIPTIONUS5554501
DESCRIPTIONUS5556752
DESCRIPTIONUS5561071
DESCRIPTIONUS5571639
DESCRIPTIONUS5580732
DESCRIPTIONUS5593839
DESCRIPTIONUS5624711
DESCRIPTIONUS5631734
DESCRIPTIONUS5661028
DESCRIPTIONUS5700637
DESCRIPTIONUS5744305
DESCRIPTIONUS5770456
DESCRIPTIONUS5770722
DESCRIPTIONUS5837832
DESCRIPTIONUS5848659
DESCRIPTIONUS5856101
DESCRIPTIONUS5874219
DESCRIPTIONUS5885837
DESCRIPTIONUS5919523
DESCRIPTIONUS6022963
DESCRIPTIONUS6077674
DESCRIPTIONUS6156501
DESCRIPTIONUS7521051
DESCRIPTIONUS8008449
DESCRIPTIONUS8354509
DESCRIPTIONUS8383796
DESCRIPTIONWO2008156712
DESCRIPTIONWO2010027827
DESCRIPTIONWO2010077634
DESCRIPTIONWO2011066342
DESCRIPTIONWO2012135408
DESCRIPTIONWO2013019906
DESCRIPTIONWO2014009535
DESCRIPTIONWO9820019
DESCRIPTIONWO9820020
INTERNATIONAL-SEARCH-REPORTUS2013178391
INTERNATIONAL-SEARCH-REPORTUS2014220580
INTERNATIONAL-SEARCH-REPORTUS2015071910
INTERNATIONAL-SEARCH-REPORTWO2015016718
INTERNATIONAL-SEARCH-REPORTWO2015094992
OPPOSITIONCA2905798
OPPOSITIONEP2535354
OPPOSITIONUS2013034540
OPPOSITIONUS2013178391
OPPOSITIONUS2015071910
OPPOSITIONWO2012135408
OPPOSITIONWO2014165422
OPPOSITIONWO2014194293
OPPOSITIONWO2015094992
OPPOSITIONWO2015094995
OPPOSITIONWO2015094996
OPPOSITIONWO2015119930
SEARCHUS2015071910
SEARCHWO2012038068
SEARCHWO2014009535
SEARCHWO2015035112

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Highlights of prescribing information", Keytruda Prescribing Information, (20140900), pages 1 - 16, XP055847902
OPPOSITION- Anonymous, "Yervoy 5 mg/ml concentrate solution for infusion' - summary of product characteristics", Electronic Medicines Compendium, (20210912), pages 1 - 28, XP055848070
OPPOSITION- BROOKS, J.D., "Translational genomics : The challenge of developing cancer biomarkers", Genome Res, (20120200), vol. 22, no. 2, pages 183 - 187, XP055848069
OPPOSITION- Goosens N., Nakagawa S., Shun X., Hoshida Y., "Cancer biomarker discovery and validation", Transl Cancer Res., (20150600), vol. 4, no. 3, pages 256 - 269, XP055847908
OPPOSITION- Lal N., Beggs A. D., Willcox B. E., Middleton G. W., "An immunogenomic stratification of colorectal cancer : Implications for development of targeted immunotherapy", Oncolmmunology, (20150300), vol. 4, no. 3, page e976052
OPPOSITION- Lal N., Beggs A. D., Willcox B. E., Middleton G. W., "An immunogenomic stratification of colorectal cancer : Implications for development of targeted immunotherapy", Oncolmmunology, (20150300), vol. 4, no. 3, page e976052, XP055248283
SEARCH- L Chow ET AL, "Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)", (20160501), URL: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.6010, (20180817), XP055500554

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents